In The News,
Rare and Ultra Rare Therapeutics
Helped both small- and mid-size pharma manufacturers understand drivers of U.S. coverage and market access for novel orphan therapeutics, including likely adoption by U.S. and global payers. Various tasks included adoption of innovative pricing arrangements, likely utilization management use, formulary or medical benefit placement, and impact of review by third-party value assessors, including ICER and NICE.